PharmaShots | Incisive News in 3 Shots

Subscribe Now

Syndax

$Syndax Reports Protocol-Defined Pooled Analysis Results from the (AUGMENT-101) Trial of Revumenib for Relapsed/Refractory KMT2Ar Acute Leukemia$

Syndax Reports Protocol-Defined Pooled Analysis Results from the (AUGMENT-101) Trial of Revumenib for Relapsed/Refractory KMT2Ar A...

October 3, 2023

Syndax and Incyte Report P-II Dose-Ranging Trial (AGAVE-201) of Axatilimab for the Treatment of Chronic Graft-Versus-Host Disease

Syndax and Incyte Report P-II Dose-Ranging Trial (AGAVE-201) of Axatilimab for the Treatment of Chronic Graft-Versus-Host Disease

July 25, 2023

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us